Extended dosing of monoclonal antibodies in multiple sclerosis

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Extended dosing of monoclonal antibodies in multiple sclerosis. / van Kempen, Zoé L.E.; Toorop, Alyssa A.; Sellebjerg, Finn; Giovannoni, Gavin; Killestein, Joep.

I: Multiple Sclerosis Journal, Bind 28, Nr. 13, 2022, s. 2001-2009.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

van Kempen, ZLE, Toorop, AA, Sellebjerg, F, Giovannoni, G & Killestein, J 2022, 'Extended dosing of monoclonal antibodies in multiple sclerosis', Multiple Sclerosis Journal, bind 28, nr. 13, s. 2001-2009. https://doi.org/10.1177/13524585211065711

APA

van Kempen, Z. L. E., Toorop, A. A., Sellebjerg, F., Giovannoni, G., & Killestein, J. (2022). Extended dosing of monoclonal antibodies in multiple sclerosis. Multiple Sclerosis Journal, 28(13), 2001-2009. https://doi.org/10.1177/13524585211065711

Vancouver

van Kempen ZLE, Toorop AA, Sellebjerg F, Giovannoni G, Killestein J. Extended dosing of monoclonal antibodies in multiple sclerosis. Multiple Sclerosis Journal. 2022;28(13):2001-2009. https://doi.org/10.1177/13524585211065711

Author

van Kempen, Zoé L.E. ; Toorop, Alyssa A. ; Sellebjerg, Finn ; Giovannoni, Gavin ; Killestein, Joep. / Extended dosing of monoclonal antibodies in multiple sclerosis. I: Multiple Sclerosis Journal. 2022 ; Bind 28, Nr. 13. s. 2001-2009.

Bibtex

@article{7e8d5ee848154ea9a13b349a4d4af1eb,
title = "Extended dosing of monoclonal antibodies in multiple sclerosis",
abstract = "Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no evidence of MS disease activity” is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-α4β1-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.",
keywords = "extended dosing, monoclonal antibodies, Multiple sclerosis, personalized dosing",
author = "{van Kempen}, {Zo{\'e} L.E.} and Toorop, {Alyssa A.} and Finn Sellebjerg and Gavin Giovannoni and Joep Killestein",
note = "Publisher Copyright: {\textcopyright} The Author(s), 2021.",
year = "2022",
doi = "10.1177/13524585211065711",
language = "English",
volume = "28",
pages = "2001--2009",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "13",

}

RIS

TY - JOUR

T1 - Extended dosing of monoclonal antibodies in multiple sclerosis

AU - van Kempen, Zoé L.E.

AU - Toorop, Alyssa A.

AU - Sellebjerg, Finn

AU - Giovannoni, Gavin

AU - Killestein, Joep

N1 - Publisher Copyright: © The Author(s), 2021.

PY - 2022

Y1 - 2022

N2 - Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no evidence of MS disease activity” is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-α4β1-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.

AB - Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no evidence of MS disease activity” is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-α4β1-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.

KW - extended dosing

KW - monoclonal antibodies

KW - Multiple sclerosis

KW - personalized dosing

U2 - 10.1177/13524585211065711

DO - 10.1177/13524585211065711

M3 - Review

C2 - 34949134

AN - SCOPUS:85122076148

VL - 28

SP - 2001

EP - 2009

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 13

ER -

ID: 330398740